Engineering Conferences International

ECI Digital Archives
Microbial Engineering II
4-3-2022

Towards a platform process for the manufacture of
glycoconjugate vaccines for pneumococcal disease
Frank Baganz
Neha Patel
Emily Kay
Jon Cuccui
Tarit Mukhopadhyay

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/microbial_ii

Proceedings

Authors
Frank Baganz, Neha Patel, Emily Kay, Jon Cuccui, Tarit Mukhopadhyay, and Michael Sulu

TOWARDS A PLATFORM PROCESS FOR THE MANUFACTURE OF GLYCOCONJUGATE VACCINES FOR
PNEUMOCOCCAL DISEASE
Frank Baganz, Department of Biochemical Engineering, University College London, United Kingdom
f.baganz@ucl.ac.uk
Neha Patel, University College London, United Kingdom
Emily Kay, London School of Hygiene and Tropical Medicine
Jon Cuccui, London School of Hygiene and Tropical Medicine
Tarit Mukhopadhyay, Merck USA
Michael Sulu, Department of Biochemical Engineering, University College London, United Kingdom
Key Words: Streptococcus pneumoniae, Glycoconjugate Vaccines, Protein Glycan Coupling Technology
(PGCT), Escherichia coli, Fed-batch process
Streptococcus pneumoniae is one of the leading causes of invasive bacterial disease in children where infection
results in pneumonia and meningitis. The introduction of glycoconjugate vaccines for the bacterium has meant a
significant reduction in cases of invasive bacterial diseases in children under the age of 5 worldwide. The
current gold standard glycoconjugate vaccine for immunization is Prevenar- 13. However, the combination of a
currently complex and long manufacturing process involving chemical conjugation means the final cost per dose
of the vaccine is high.
The advent of Protein Glycan Coupling Technology (PGCT) has therefore been an important development. This
recombinant process is able to produce glycoconjugate vaccines intracellularly in E. coli (1, 2). As a result, this
reduces the number of steps required in the manufacturing process, meaning it presents itself as an attractive
alternative to the current manufacturing process. This work aims to develop a platform process for
glycoconjugate vaccines.
First, E.coli cells have been engineered to produce a
glycoconjugate of serotype 4 of S.pneumoniae. Fedbatch fermentations with an initial cell line
demonstrated the need to further optimize the PGCT
system. To this end new strains were engineered which
introduced a different acceptor protein (ExoA), or had
the glycosyltransferase enzyme PglB, catalyzing the
glycoconjugation, either integrated in the chromosome
or expressed from a plasmid. Fed-batch fermentations
with these four strains found that the introduction of the
ExoA acceptor protein had a greater impact in
improving the glycoconjugate production compared to
the location of the PglB enzyme as shown in Figure 1.

Figure 1- Immunoblot comparing end point
samples (28 hours post induction) from fed batch
fermentations. 11µL of lysate OD600 matched to 2.5
run in each lane. M is the molecular weight marker.
From left to right; Strain 1: ExoA acceptor protein
PglB chromosomal (lanes 1 and 2), Strain 2: ExoA
acceptor protein PglB plasmidic (lanes 3 and 4),
Strain 3; PiuA acceptor protein PglB chromosomal
(lanes 5 and 6), Strain 4: ExoA acceptor protein
PglB plasmidic (lanes 7 and 8).

Thus, strain 1 was selected for further process
optimization and used in a small Design of Experiment
study looking at three factors i.e. pre-induction growth
rate, post-induction temperature and feed rate. Here a
condition has been identified which improves product
formation by 1.9 fold compared to the standard fed-bath
process.
In summary, initial optimisation of both the PGCT
system and the fermentation process has been
performed to improve the glycoconjugate production.
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